Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

GLP-1RA weight-loss drugs provide health benefits but also pose risks, including pancreatitis, kidney problems, and ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

March of Dimes, the organization fighting for the health of all moms and babies, has named Dr. Kimberly O'Brien, Professor of ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

While Ozempic has been praised for its ability to induce weight loss and treat a range of health conditions, it could also ...